Investigating how a specific protein interaction affects a type of leukemia
The Role of HIF1A-DNMT3A axis in AML1/ETO-Driven Acute MyelogenousLeukemia
This study is looking into how certain signals in the body affect the progression and relapse of acute myeloid leukemia (AML) caused by a specific protein, with the hope of finding new ways to create better treatments for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-10993645 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of the HIF1A-DNMT3A signaling axis in acute myeloid leukemia (AML) driven by the AML1/ETO fusion protein. The study aims to uncover the mechanisms behind the disease's progression and the reasons for relapse in patients with this leukemia subtype. By exploring the molecular interactions and effects of hypoxia-independent signaling, the research seeks to identify new therapeutic targets and develop effective treatments for AML. Patients may benefit from insights that could lead to more personalized and effective therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia, particularly those with the AML1/ETO fusion protein.
Not a fit: Patients with other subtypes of leukemia or those without the AML1/ETO fusion protein may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that improve outcomes for patients with acute myeloid leukemia.
How similar studies have performed: Other research has shown promise in targeting similar molecular pathways in leukemia, suggesting potential for success in this approach.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Liu, Shujun — Case Western Reserve University
- Study coordinator: Liu, Shujun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.